Cellectar Biosciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

FIXED ASSETS

FIXED ASSETS

12 Months Ended

Dec. 31, 2014

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment Disclosure [Text Block]

5. FIXED ASSETS

Fixed assets consisted of the following at December 31:

	2014		2013

Office and laboratory equipment	$	3,317,386	$	3,296,810
Computer software		4,000		4,000
Leasehold improvements		2,324,672		2,324,672
Total fixed assets		5,646,058		5,625,482
Less– accumulated depreciation and amortization		(3,612,114)		(3,264,948)
Fixed assets, net	$	2,033,944	$	2,360,534

For the years ended December 31, 2014 and 2013, the Company incurred approximately $367,000 and $425,000 of depreciation and amortization expense, respectively.

- Definition

The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.

+ References + Details